Rapamycin for Vitiligo

Phase-Based Progress Estimates
VitiligoRapamycin - Drug
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether a drug called rapamycin can treat vitiligo. People will apply it to one side of their body and a placebo to the other to see if there's a difference. The study will also see if patients are happy with the treatment and if there are any side effects.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 6 months

6 months
Average score of Dermatology Quality of Life questionnaire (or Teenager Quality of Life Index)
Number of lesions with no response
Number of lesions with partial response
Numbers of lesions with complete response

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

CNI Group
14%acute kidney failure
This histogram enumerates side effects from a completed 2009 Phase 4 trial (NCT00223678) in the CNI Group ARM group. Side effects include: pneumonia with 14%, acute kidney failure with 14%.

Trial Design

3 Treatment Groups

Topical rapamycin 0.1%
1 of 3
Topical rapamycin 0.001%
1 of 3
1 of 3

Active Control

Experimental Treatment

Non-Treatment Group

20 Total Participants · 3 Treatment Groups

Primary Treatment: Rapamycin · Has Placebo Group · Phase 2

Topical rapamycin 0.001%
Experimental Group · 1 Intervention: Rapamycin · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Topical rapamycin 0.1%
ActiveComparator Group · 1 Intervention: Rapamycin · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
837 Previous Clinical Trials
5,378,570 Total Patients Enrolled
1 Trials studying Vitiligo
4 Patients Enrolled for Vitiligo
American Skin AssociationOTHER
2 Previous Clinical Trials
42 Total Patients Enrolled
1 Trials studying Vitiligo
12 Patients Enrolled for Vitiligo
Ahmad Aleisa, MDPrincipal InvestigatorMedical University of South Carolina

Eligibility Criteria

Age Any Age · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have nonsegmental vitiligo.

Who else is applying?

What state do they live in?
New Jersey16.7%
How old are they?
18 - 6566.7%
< 1833.3%
What site did they apply to?
Medical University of South Carolina100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria33.3%
Met criteria66.7%

How responsive is this trial?

Typically responds via